中恆集團(600252.SH):南寧中恆投資擬投建中恆醫藥智造谷
格隆匯3月7日丨中恆集團(600252.SH)發佈,2022年3月7日,公司召開了第九屆董事會第三十六次會議,會議審議通過了《中恆集團關於開發建設中恆醫藥智造谷的議案》。董事會同意公司控股孫公司南寧中恆投資開發建設中恆醫藥智造谷項目,項目總投資估算約4.32億元,規劃總建築面積138,415.60㎡。董事會授權公司經營層根據實際情況負責具體組織該項目實施工作。
為了緊抓實體經濟發展和經開區產業發展趨勢,中恆集團控股子公司廣西梧州製藥(集團)股份有限公司的全資子公司南寧中恆投資擬投資中恆南寧醫藥產業基地C地塊作為首期開發標準園區項目,以招引實體制造業企業,形成成長性好、科技含量高的新型產業集羣,在實現企業效益的同時助力經開區產業升級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.